[go: up one dir, main page]

BR0112417A - Composições farmacêuticas contendo composto dds - Google Patents

Composições farmacêuticas contendo composto dds

Info

Publication number
BR0112417A
BR0112417A BR0112417-0A BR0112417A BR0112417A BR 0112417 A BR0112417 A BR 0112417A BR 0112417 A BR0112417 A BR 0112417A BR 0112417 A BR0112417 A BR 0112417A
Authority
BR
Brazil
Prior art keywords
compositions containing
pharmaceutical compositions
compound
dds compound
containing dds
Prior art date
Application number
BR0112417-0A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of BR0112417A publication Critical patent/BR0112417A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS CONTENDO COMPOSTO DDS". Uma composição farmacêutica tendo estabilidade assegurada de preservação, a qual contém um composto, onde um derivado de polissacarídeos tendo um grupo de carboxila é ligado a um derivado de camptotecina através de um espaçador ou sem ser mediado por espaçador, e um açúcar ou álcool de açúcar opcionalmente juntamente com uma substância para ajuste de pH.
BR0112417-0A 2000-07-13 2001-07-11 Composições farmacêuticas contendo composto dds BR0112417A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000213083 2000-07-13
PCT/JP2001/006020 WO2002005855A1 (fr) 2000-07-13 2001-07-11 Compositions pharmaceutiques contenant des composes dds

Publications (1)

Publication Number Publication Date
BR0112417A true BR0112417A (pt) 2003-07-01

Family

ID=18708899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112417-0A BR0112417A (pt) 2000-07-13 2001-07-11 Composições farmacêuticas contendo composto dds

Country Status (12)

Country Link
US (1) US6815435B2 (pt)
EP (1) EP1308171A1 (pt)
KR (1) KR20030023697A (pt)
CN (1) CN1556712A (pt)
AR (1) AR031714A1 (pt)
AU (1) AU2001271037A1 (pt)
BR (1) BR0112417A (pt)
CA (1) CA2415922A1 (pt)
MX (1) MXPA03000387A (pt)
NO (1) NO20030139L (pt)
RU (1) RU2003100532A (pt)
WO (1) WO2002005855A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000734A1 (fr) * 2000-06-29 2002-01-03 Daiichi Pharmaceutical Co., Ltd. Compose dds et son procede de preparation
TWI320713B (pt) * 2001-06-01 2010-02-21 Neochemir Inc
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
CN100366261C (zh) * 2002-12-10 2008-02-06 田中雅也 皮肤外用材料及使用其的外用止痒剂和去皱用品
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
AU2013263795B2 (en) * 2010-03-29 2015-09-17 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
ES2643087T3 (es) * 2010-03-29 2017-11-21 Ferring B.V. Composición farmacéutica de disolución rápida
CN103781467B (zh) 2011-09-16 2016-08-31 辉凌公司 一种快速溶解药物组合物
BR122021014396B1 (pt) 2012-10-11 2022-07-05 Daiichi Sankyo Company, Limited Compostos intermediários ligantes de fármacos, e ligante
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
KR102535900B1 (ko) 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
BR112016013482B1 (pt) 2014-01-31 2022-04-19 Daiichi Sankyo Company, Limited Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
AU2015369185B2 (en) 2014-12-26 2020-10-22 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
JP6735759B2 (ja) 2015-09-03 2020-08-05 日本化薬株式会社 カンプトテシン類高分子誘導体を含有する医薬組成物
JP6797182B2 (ja) 2016-03-01 2020-12-09 日本化薬株式会社 カンプトテシン類高分子誘導体を含有する医薬製剤
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
CN112351999A (zh) 2018-05-18 2021-02-09 第一三共株式会社 抗-muc1抗体-药物缀合物
TWI822822B (zh) 2018-07-31 2023-11-21 日商第一三共股份有限公司 抗體-藥物結合物之用途
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
WO2021007435A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
EP0857484A4 (en) 1995-09-13 2000-12-06 Nippon Shinyaku Co Ltd PGE1- FREEZING DRIED PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
PL328309A1 (en) * 1996-02-19 1999-01-18 Nycomed Imaging As Thermally stabilised contrast medium
AU2034097A (en) * 1996-03-19 1997-10-10 Morgan Crucible Company Plc, The A conduit
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6583164B1 (en) 1998-09-29 2003-06-24 Takeda Chemical Industries, Ltd. Antimycotic drug composition

Also Published As

Publication number Publication date
EP1308171A1 (en) 2003-05-07
KR20030023697A (ko) 2003-03-19
WO2002005855A1 (fr) 2002-01-24
NO20030139L (no) 2003-03-13
NO20030139D0 (no) 2003-01-10
MXPA03000387A (es) 2003-09-22
CA2415922A1 (en) 2002-01-24
CN1556712A (zh) 2004-12-22
AU2001271037A1 (en) 2002-01-30
US6815435B2 (en) 2004-11-09
US20030148931A1 (en) 2003-08-07
AR031714A1 (es) 2003-10-01
RU2003100532A (ru) 2004-07-20

Similar Documents

Publication Publication Date Title
BR0112417A (pt) Composições farmacêuticas contendo composto dds
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
HRP20020880B1 (en) New pharmaceutical composition
CY1105388T1 (el) Μορφη δοσολογιας πepιλαμβανουσα θepαπευτικο σκευασμα
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NZ501950A (en) Medicinal compositions for application to mucosa
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
ATE422356T1 (de) Pharmazeutische zubereitungen
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
YU59201A (sh) Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina
RS50348B (sr) Farmaceutski oblik dronedarona za parenteralnu upotrebu
RS50310B (sr) Farmaceutska kompozicija koja sadrži ciklesonid za primenu na sluzokoži
KR880007060A (ko) 제약 조성물
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
BR0109891A (pt) Composição farmaceutica contendo derivado de camptotecina e substância de ajuste de ph

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4745 (2006.01), A61K 9/00 (2006.01), A61K